<DOC>
	<DOCNO>NCT02836483</DOCNO>
	<brief_summary>A Prospective , Randomized , Open , Active-controlled , Interventional , Exploratory , Phase II Trial LCB01-0371 .</brief_summary>
	<brief_title>A Clinical Study LCB01-0371</brief_title>
	<detailed_description>This study design explore antituberculosis LCB01-0371 ass early bactericidal activity , safety administration .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Tuberculosis , Pulmonary</mesh_term>
	<mesh_term>Linezolid</mesh_term>
	<criteria>1 . Korean After listen understand detail clinical trial , decide join clinical study , write consent 2 . The age consent time write , men woman 50 year old 19 year old 3 . The First diagnosis tuberculosis receive tuberculosis treatment TB patient 1 . Known history Rifampicin Isoniazid resistance , and/or confirm resistant Xpert MTB RIF test result 2 . Serious TB example tuberculous encephalomeningitis , It impossible participate clinical trial 3 . Known History nontuberculous mycobacteria positive 4 . It impossible participate clinical trial except TB</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>